A Phase 1b Study of MRX-2843 and Osimertinib in EGFR Mutant NSCLC

Recruiting Phase 1 NCT04762199

Study Description

A Study Evaluating the Safety and Efficacy of MRX-2843 in Combination with Osimertinib for Advanced EGFR Mutant Non-Small Cell Lung Cancer

Study Details

Registry ID:
NCT04762199
Conditions:
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Phase:
Phase 1
Target Enrollment:
69 participants
Start Date:
Age Range:
18–999 years
Healthy Volunteers:
No

Study Locations (1 site)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →